The briefing
Medical Xpress reports that a Weill Cornell Medicine–led team found a common vulnerability across multiple cancers and has begun designing compounds to exploit it. The approach could enable potent treatments with fewer side effects for colorectal, breast, and other cancers, pending further study.
Original headline
New strategy may target common cancer driver with minimal side effects